These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 29208248

  • 1. Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options.
    Sanghera P, Ghanta M, Ozay F, Ariyamuthu VK, Tanriover B.
    Am J Med Sci; 2017 Dec; 354(6):533-538. PubMed ID: 29208248
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of C3 glomerulopathy with complement blockers.
    Vivarelli M, Emma F.
    Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
    Garg N, Zhang Y, Nicholson-Weller A, Khankin EV, Borsa NG, Meyer NC, McDermott S, Stillman IE, Rennke HG, Smith RJ, Pavlakis M.
    Nephrol Dial Transplant; 2018 Dec 01; 33(12):2260-2265. PubMed ID: 29370420
    [Abstract] [Full Text] [Related]

  • 8. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS).
    Sethi S, Fervenza FC.
    Semin Thromb Hemost; 2014 Jun 01; 40(4):416-21. PubMed ID: 24799306
    [Abstract] [Full Text] [Related]

  • 9. C3 glomerulopathy and current dilemmas.
    Ito N, Ohashi R, Nagata M.
    Clin Exp Nephrol; 2017 Aug 01; 21(4):541-551. PubMed ID: 27878657
    [Abstract] [Full Text] [Related]

  • 10. Complement dysregulation in glomerulonephritis.
    Kaartinen K, Safa A, Kotha S, Ratti G, Meri S.
    Semin Immunol; 2019 Oct 01; 45():101331. PubMed ID: 31711769
    [Abstract] [Full Text] [Related]

  • 11. C3 Glomerulopathy: Pathogenesis and Treatment.
    Ahmad SB, Bomback AS.
    Adv Chronic Kidney Dis; 2020 Mar 01; 27(2):104-110. PubMed ID: 32553242
    [Abstract] [Full Text] [Related]

  • 12. C3 glomerulopathy.
    Servais A, Noël LH, Frémeaux-Bacchi V, Lesavre P.
    Contrib Nephrol; 2013 Mar 01; 181():185-93. PubMed ID: 23689580
    [Abstract] [Full Text] [Related]

  • 13. A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug intervention.
    Zewde N, Morikis D.
    PLoS One; 2018 Mar 01; 13(6):e0198644. PubMed ID: 29874282
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Eculizumab in the treatment of membranoproliferative glomerulonephritis.
    Bomback AS.
    Nephron Clin Pract; 2014 Mar 01; 128(3-4):270-6. PubMed ID: 25402185
    [Abstract] [Full Text] [Related]

  • 20. Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?
    Ankawi GA, Clark WF.
    BMJ Case Rep; 2017 Aug 10; 2017():. PubMed ID: 28798244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.